<SEC-DOCUMENT>0001144204-14-008614.txt : 20140213
<SEC-HEADER>0001144204-14-008614.hdr.sgml : 20140213
<ACCEPTANCE-DATETIME>20140213171631
ACCESSION NUMBER:		0001144204-14-008614
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140211
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140213
DATE AS OF CHANGE:		20140213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-119366
		FILM NUMBER:		14607832

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v368520_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report: February 11, 2014<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>333-119366</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3301 Agriculture Drive, Madison, Wisconsin
53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Item 5.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENTS
TO ARTICLES OF INCORPORATION OR BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 11, 2014, we changed our name from Novelos Therapeutics,
Inc. to Cellectar Biosciences, Inc. The name change was effected pursuant to the short form merger of a wholly owned Delaware subsidiary
named Cellectar Biosciences, Inc. with and into Novelos Therapeutics, Inc. which resulted in the change to the name of the parent
company to Cellectar Biosciences, Inc. The Certificate of Ownership and Merger effecting the change is filed as Exhibit 3.1 and
is incorporated by reference in this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ticker symbol of our common stock was changed from NVLT
to CLRB in connection with the name change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REGULATION
FD DISCLOSURE &nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release issued by us on February 11, 2014
announcing the change to our corporate name is furnished as Exhibit 99.1 and is incorporated by reference in this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate of Ownership and Merger of Cellectar Biosciences,
        Inc. with and into Novelos Therapeutics, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release dated February 11, 2014 entitled &ldquo;Novelos
        Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.&rdquo;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>CELLECTAR BIOSCIENCES, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Dated: February 13, 2014 &#9;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%"><I>/s/ Joanne M. Protano</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name: Joanne M. Protano<BR>Title: Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">3.1</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate of Ownership and Merger of Cellectar Biosciences,
        Inc. with and into Novelos Therapeutics, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Press Release dated February 11, 2014 entitled &ldquo;Novelos
        Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.&rdquo;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>v368520_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF OWNERSHIP AND MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CELLECTAR
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>WITH
AND INTO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 253 of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>General Corporation Law of the State
of Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Novelos Therapeutics, Inc., a Delaware corporation
(the &ldquo;Corporation&rdquo;), does hereby certify to the following facts relating to the merger (the &ldquo;Merger&rdquo;) of
Cellectar Biosciences, Inc., a Delaware corporation (&ldquo;Cellectar&rdquo;), with and into the Corporation, with the Corporation
remaining as the surviving corporation under the name of Cellectar Biosciences, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">FIRST:</TD><TD>The Corporation and Cellectar are incorporated pursuant to the General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">SECOND:</TD><TD>The Corporation and Cellectar are the constituent corporations in the Merger.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">THIRD:</TD><TD>The Corporation owns all of the outstanding shares of capital stock of Cellectar.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">FOURTH:</TD><TD>The Board of Directors of the Corporation, by the following resolutions adopted on February 1, 2014 by unanimous vote, duly
determined to merge Cellectar with and into the Corporation:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED:&#9;That the Corporation
hereby approves the formation and capitalization of its subsidiary Cellectar Biosciences, Inc., a Delaware corporation (&ldquo;CBI&rdquo;),
of which the Corporation will be the sole shareholder, and that the officers of the Corporation be, and they hereby are, and each
of them acting singly hereby is, authorized, for and on behalf of the Corporation and in its name, to prepare, execute, acknowledge,
file, record and deliver, under seal if required or desirable, all such agreements, instruments and other documents, and to take
such other actions, as they shall deem necessary or desirable in the formation of such subsidiary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED:&#9;That the Corporation
effect the merger of CBI with and into the Corporation, with the Corporation assuming all of CBI&rsquo;s liabilities and obligations,
pursuant to Section 253 of the DGCL (the &ldquo;<U>Merger</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED:&#9;That by virtue of
the Merger and without any action on the part of the holder thereof, each then outstanding share of common stock of the Corporation,
and each security or instrument convertible into shares of common stock of the Corporation, shall remain unchanged and continue
to remain outstanding and held by the person who was the holder of such share, security or instrument, as the case may be, immediately
prior to the Merger;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED:&#9;That by virtue of
the Merger and without any action on the part of the holder thereof, each then outstanding share of common stock of CBI shall be
cancelled and no consideration shall be issued in respect thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED:&#9;That the certificate
of incorporation of the Corporation and the by-laws as in effect immediately prior to the effective time of the Merger shall be
the certificate of incorporation of the surviving corporation; provided, however, that following the Merger, the name of the Corporation
shall be &ldquo;Cellectar Biosciences, Inc.&rdquo; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">RESOLVED: &#9;That the officers
of the Corporation be, and they hereby are, and each of them acting singly hereby is, authorized and directed to make, execute
and acknowledge, in the name and on behalf of the Corporation, a Certificate of Ownership and Merger for the purpose of effecting
the Merger and to file the same in the office of the Secretary of State of the State of Delaware, and to do all other acts and
things that may be necessary or advisable to carry out and effectuate the purpose and intent of the resolutions relating to the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">FIFTH:</TD><TD>The Corporation shall be the surviving corporation
of the Merger.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">SIXTH:</TD><TD>Notwithstanding the date on which this Certificate of Ownership and Merger is filed, this Certificate of Ownership and Merger
shall become effective on February 11, 2014 at 11:59 p.m.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">****&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation
has caused this Certificate of Ownership and Merger to be executed by its duly authorized officer this 7th day of February, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">NOVELOS THERAPEUTICS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%"><I>/s/ Joanne M. Protano</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&#9;Joanne M. Protano<BR>Title: &#9;Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v368520_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD>
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Novelos
Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>Stock to be Quoted Under Ticker
Symbol CLRB Beginning February 12, 2014</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., February 11, 2014,</B>
&ndash; Novelos Therapeutics, Inc. (OTCQX: NVLT)<B> </B>a biopharmaceutical company developing novel agents for the detection and
treatment of cancer, announced that, effective today, its corporate name will be &quot;Cellectar Biosciences, Inc.&quot; The company's
shares will start trading under its new name and stock ticker symbol, &quot;CLRB&quot;, effective as of market open on February
12, 2014. The company's common stock has been assigned a new CUSIP number of 15117F104 in connection with the name change.&nbsp;Outstanding
stock certificates are not affected by the name change and will not need to be exchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;Over the course of the last few months,
we have undertaken a thorough evaluation of our development pipeline and business strategy with an eye toward taking the necessary
steps to begin rebuilding shareholder value,&rdquo; commented Dr. Simon Pedder, acting chief executive officer. &ldquo;As part
of this process we have implemented organizational and personnel changes, sought additional capital and defined clinical development
programs that target areas of high unmet medical need, provide an opportunity to validate our technology and allow us to firmly
establish proof-of-concept for our highly-selective cancer-targeting and retention delivery platform. With the right team and the
right programs, we are now poised to execute on the near-term opportunities that will provide the foundation for our future growth
and success. We look forward to starting this new chapter and are proud to do so under a new name that reflects the origins of
our technology and the simplicity of our mission to create cancer and cancer stem cell selective technology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A New Approach to Cancer Treatment,
Detection and Monitoring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar is developing a portfolio of
imaging and therapeutic agents that capitalize on the unique attributes of its cancer-targeting and retention platform technology.
Because of the variety of agents that preclinical data suggest can be effectively linked to Cellectar&rsquo;s phospholipid ether
(PLE) platform, the opportunities for development span a broad range of uses and indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, three cancer-targeted products
have been generated from a single chemical core structure that is the foundation of our technology platform: a diagnostic PET imaging
agent, I-124-CLR1404; a molecular radiotherapeutic, I-131-CLR1404; and a non-radioactive optical imaging agent designed to increase
the success of cancer surgery and non-invasively image certain tumors, CLR1502.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Together, our agents are being developed
to &ldquo;find, treat and follow&rdquo; cancer anywhere in the body in a novel and highly selective way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Focused on Disciplined Execution and
Validation of Technology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maximize the future value of
Cellectar&rsquo;s core technology, the company is focused on targeting rapid development opportunities that can validate the delivery
technology and optimize internal resources while firmly establishing proof-of-concept where there is significant unmet medical
need. To this end, Cellectar&rsquo;s initial strategic priorities will be to advance its tumor imaging clinical programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar will initiate its first company-sponsored
Phase II trial evaluating I-124-CLR1404 in glioblastoma in the first quarter of 2014. This 10-center trial is expected enroll approximately
36 patients and be completed by year-end 2014. Though identified as an orphan indication, glioblastoma is the most common malignant
primary brain tumor. Glioblastomas are aggressive tumors with rapid progression and limited treatment options that typically results
in death within 15 months of diagnosis. Despite complete resection of glioblastoma defined by conventional MRI, local recurrence
is essentially universal suggesting MRI inadequately defines the true extent of disease. Moreover, conventional imaging is inadequate
in distinguishing recurrent glioblastoma from treatment related changes and pseudoprogression. Cellectar&rsquo;s novel Phase II
trial design seeks to demonstrate that PET imaging using I-124-CLR1404 can enable more definitive and precise diagnostic imaging
of glioblastoma as conclusively confirmed by pathologic analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to its PET imaging agent, Cellectar
is developing CLR1502 for real-time, intraoperative imaging of cancer to aid in the identification of malignant tissue during diagnostic,
staging, debulking and curative cancer surgeries. The company plans to submit an Investigational New Drug (IND) application in
2014 to enable the initiation of a Phase I trial of its optical imaging agent, CLR1502, in patients undergoing breast cancer conserving
surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;We believe the integration of pathology
confirmation in our imaging studies provides a unique opportunity to rapidly, and compellingly, validate our broader portfolio
opportunities and look forward to leveraging the data generated by these trials to facilitate the future advancement of additional
imaging and therapeutic candidates, both on our own and in partnership with other companies,&quot; continued Dr. Pedder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether (PLE) platform technology as a targeted
delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in both cancer
cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform,
Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells
to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent. A Phase II trial evaluating I-124-CLR1404 in glioblastoma is expected to be completed in 2014.
Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404
is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and
selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose-escalation trial of I-131-CLR1404 in patients with
advanced solid tumors is anticipated in the first quarter of 2014. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical
imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit
www.cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: kmcneil@cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
&quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp; pharmaceutical collaborators' ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2012 and in our subsequent quarterly reports on Form 10-Q. These
forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!*`,X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UOPAXLM_$
MM@#D)>1C$L6?U'M725\S:7J=UI%_'>6<A26,YXZ$>AKWOPMXGM?$NG":,A+A
M!B6+/*G_``KNQ>%=)\T=OR/,P&.59<D_B_,WJ***X3TREK&HC2=(NK]HS(($
MWE0<9K#\)>,H_%4EPB6C0>2`3N;.<U<\9?\`(G:I_P!<#7"_!_\`X^=2_P!Q
M?YUUTZ47AY3>Z."K7G'%0IIZ-'J]%%%<AWA1110`4444`%%%%`!1110`5S'Q
M!_Y$N_\`]T?SKIZYCX@_\B7?_P"Z/YUK0_BQ]488G^#/T9SOP@_Y!FH_]=5_
ME7I->;?"#_D&:C_UU7^5>DUIC/X\C'+_`/=HA1117,=H4444`%%%%`'A7P\T
MRUUC6+FSNXP\4ENP]P?44V_L=5^'WB)9X&)BSF-_X9%]#5[X4?\`(T2_]<#7
MK.LZ-::YITEG=H&1A\K=U/J*]>OB/9UW&6L6M3P,+A/;892CI)-V96\.>(K3
MQ'IJW-NP$@&)8B>4-;->#R1ZM\._$@923&3P?X94_P`:]ET+7;3Q!IJ7EHXY
MX=.Z'T-<6(P_)[\-8L]'!XMU?W=32:W*OC+_`)$[5/\`K@:X7X/_`/'SJ7^X
MO\Z[KQE_R)VJ?]<#7"_"#BXU(G^XO\ZUI?[K/U_R,:_^_4_3_,]7)`&2<`54
M@U2QN;MK6"[BDG099$;)`KROQGXQOM8U1M%T9G$(;RR8_O2M_A71>`O!=[X?
MN)+^^F7S9H]OE#DK]36<L,H4^>;LWLC:.,=2M[.E&Z6[.GN=9\GQ)9Z0L6XS
MQ/*SY^Z!4^JZS9:/"DEW(09&"(BC+,3Z"N:UF[.B^+)=7NX]T(M1%:JO+2N3
MR`*FTG2WEO?[>\0RQK=,,P0.P"P+^/>L(.G)Z]/Q.VM1KTH*6C4MGT6AT9U2
MP5Q&UW"LG]QG`(_"K=>/?$[2EAU"WURR8-#<<,Z'(WCO7H?@[61KGANVN"V9
M47RY1_M"M:E!1I*I%[G)1Q3G6E1DK-;>9O55DU*QBF,4EW`D@."I<`TFIWT>
MF:;<7LQ`2%"QS7BOA>W;Q#XMFU.^/^CP$W,['IQT%%&A[2,I-V2#$XITIQA%
M7;/<I)HH8C)+(J(.2S'`K'?QAX>CD\MM6M@W3&ZO*-6U?5_'>O?8K'?]GW8C
MB!PH7^\U=!!\(%-MF?4R)R.B)\H-:_5J=-+VTK-]#G^NUJK?U>%TNK/2[6]M
MKV+S+6>.9/5&S7/_`!!_Y$N__P!T?SKS"ZM-<^'FL1R)*3$QRK*?DD'H17?^
M)=6AUOX:3W\/W9$&5_NG/(H^K^SJ0E%WBV/ZW[6E4A-6DD]#-^$'_(,U'_KJ
MO\J]()"@EB`!U)KS7X1,J:5J3L0%64$D]ABL7Q/XJU/Q5K/]D:.9!;[]BK&<
M&3W)]*JK0E5Q$DM$B*&)C0PD&]6]E\STVY\5:%:2&.?5+9''4;L_RJW9:MI^
MI#-G>0S?[C<UYQ8_")G@#W^HE)2,E8USC\363K?@75_"H_M+3KIIHHSDO'PR
M?4>E2J&'D^6,]2GBL5!<\Z>GXGM50W5W;V4)FN9DAC'5G;`KDO`7C`^(;1K6
M[(%]".3_`'QZUP_B*XOO&'CDZ5'-LA67RHU)^4`=3CUK.&%DZCA/2VYM5QT5
M2C.FKN6B/5K/Q+HM_/Y-KJ5O+)_=#<UJUX]K/POO]-BAGTFX>ZD#`,H&U@?4
M>U>G>'HM2@T2WBU5U>[1<,RG.1VS[TJU*G&*E3E<K#UZTY.%6%G^!Y3\*/\`
MD:)?^N!KVFO%OA1_R-$O_7`U[36F8?QC'*O]W^;,K7]!M/$.FO:72C/5'`Y0
M^HKQR"?5OAYXD*."8R?F7^&5/45[Q6+XE\.6GB336MYU"RJ,Q2@<H?\`"HP^
M(Y/<GK%FF,PCJ?O*>DT9NMZO::W\/M0O+.0,CVYR.ZGC@UY_X%NVL=#\17*'
M#);#!_2L6Y.K>%)K_29LK'.A1U/W7'9A70?#NR.I:9KUF.LMN%'U[5W^RC2H
MRUNFT_EH>7[>5?$1NK22:^>I9^$VG1W.HWFHR@,\("H3V)ZFM'QYX\U#2-6_
MLW32L9C4-)(RY))["L3X;ZRFAZ_<:=>GREG.S+<;7!KL_%O@"W\2W:WL-S]G
MN-H5CC*L.U>?F:G[1V/H.&JF%BE[=:*]_7S,_P`%:A#XQEDN]3BW:A:)L213
M\N#W`[&KLV@^$[*\^SZG?O-<,0?+N9R<YZ<5I>&_#=EX-TN8M/N9OGFF?@<?
MTKS*25O&/Q&22`$Q&88/HB]ZC!T'*\I.UNI><X^,9NG0UC)I)/M_E<]4USP[
M:W_A:;2K>%8T5,PJHX5AR*\Z^&.KOIFO3Z1<G:LY(`/9Q7L0&``.U>+_`!`T
MR30/%<6JVHVQS,)5([..HKIPLO:*5&77\SRL=#V4H8B'V='Z'0?%?6_)LH-(
MB;YYCYDN/[HZ"L]--?P]\*;FX*[;F^*[CW"GH*P=/%QXZ\<1RSJ=C,'D'947
MM7J/CG3C>>#;N"!>8E#JH_V:UDU14*/G=G/%/$.KB%V:1Y-X3\6_\(M]H=+%
M)Y9L#>S8P/2NH_X6_<?]`J/_`+[--^%5W82&ZTV[AA:9B)(C(@)/J!FO3_[-
ML/\`GRMO^_2_X48FI2C5:G"[]1X*C7G13IU++M8\9\3>/CXDTHV4VFQQD,&6
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M#>QKFOA'J%Q_:=WIQ8FW\@S`>C!E']36,Z5*K2=6FK6W1TTJU:A65"L[I[,;
M\,M*O[+Q'))<V<T*&$C<ZD"O7:**YJ]9UI\S1V8;#K#T^1.X4445B=!@>*O"
M]KXETXQ.`ER@S%+CD'T^E<G\,M-NM)U?5K.[C*2QJH.>_/45Z73!%&)C*$42
M$;2V.2*WC7DJ;IO9G-/"PE6C66C7XGGOC?X?OJ4[:GI("W)YDBZ;SZCWKD[;
MQ5XP\/K]DD24A.`L\1;'XU[C37CCD^^BM]1FM:>+:CR5(\R,*N`3G[2E)Q;[
M'AL]YXO\92"V:.9HB>55-B#ZUZ3X,\&Q>&;8RRE9;Z4?.XZ*/05U2JJ#"J%'
MH!2U-7%.<>2*LBJ&!C3G[2;YI=V%<WXXT0:WX:GC5<SPCS8OJ.U=)01D8/0U
MSPFX24ET.NI352#A+9G`?"[0C8:1)J,R8FN3A<CD**[YE5T*L`588(/>D1$B
M0(BA5'0`<"DDD6)=S9ZX`'>JJU'4FYLBA15&FJ:Z'D7BCP'J6D:DVIZ$'>'=
MO"QGYXS_`(56A^(?BNUB\B6W$CJ,!G@.ZO9T<.@89P?6F/%#R[QH<#))45TK
M%WBE4CS6..67N,G*C-QN>*P:+XH\<ZBD]^)$A!YDD7:JCV%=[X@T"/3?A]<:
M9IT+.0HX499SGDUV*D%05^Z1D4*ZMG:<X.#[&HGBI2:LK)=#2G@80C*[NY=3
MS_X5V%U8Z=?K=V\D):52`ZXSQ5#QC\/;DWK:KH0^<G>\*G!!]5KU"D)"J23@
M#J:7UJ:JNHNH_J--T51EK;J>+V_CKQ;I2?9KB!I"G`,T)W?GWJ"9_%_CB987
MCE$&>FW9&ON?6O;3'%+AF1&]"5S2(Z>8T2#!49.!P*U^MQ6L8),Q_L^<O=G5
M;CV.=\-^#K/0M&EM'Q+-<+B>3'7/8>U>;ZAH.O\`@C6VO--61X,G9(B[@5]&
M%>UR3)%C><9Z4[AAR,@UE3Q4XR;EK?<VJX&G.$8Q]UQV:/$-1\4^*?%$`TT6
MSA).&6*(C=]37H7@3PF?#FG-)<@&]G^_C^`<?+^E=6D4<9RD:KGT&*?3JXGF
MAR0C9"H8+DJ>TJ2YI!1117*=P4444`%%%%`!1110`4444`%%%%`!56]C6180
MPSB5:M4A`/4`X.>:`,NWC\Y)3(S':GRC/0\\TS<DMG.\\I$JJ0OS8(&.,5K"
M-%!"HHSUP*8UK;NP9H(F(&`2@-`"6SAH(U!RP1<CTXK/6%3=LBLR[I6+`'J,
M5JJBJ254#/7`IOE1B3S!&N\_Q;>?SH`R%=U19"P$@8Y^;)^F*1R"T8R,2(Q8
M;\D\=ZUOL\'F&3R8_,/5MHS^=(MI;(<K;Q`^R"F`ELT8AC1&'"`XS5.1%6^D
MR2L;LH<Y]JT$BCC^Y&J\8^48XH:*-PP>-6#=01G-(#*GQYK)&=T2YV\YP<<T
M_*FU:0R$7.[&-W(YZ8^E:*P0HH58D51T`48H^SP^;YGDQ^8/XMHS^=`&9]HE
M5A(S-BV^60>N:T+4_N0K-N<#+>V>:D,49#`QJ0WWN.OUIP5020H!/4@=:`/_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!=`5T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HJ
MCJNL6&B6+WFHW*6\"]V/+'T`ZD^PKR;Q!\8KVX=H=!MEM8>@N)U#2'W"]!^.
M:VI8>I5^%";2/9Z*^:+37]8U7Q%IK7^J7<^;N+Y6E.W[X_A''Z5]+U6(P[HV
M3=[@G<9+(L,+RM]U%+'Z"O*_ACXIUSQ!XFU%+Z]:>U,)F$;*,1DL`H7`X&">
M*]`\4S26_A359(E+2"UD"`=22I`_G7G_`,&--EMEU>YFB:-B8HEW#'0$G^8J
MJ2BJ,V]]!/<]7HHKR/XB?$4NTFA:#*22?+N+F+DD]/+3'?L2/H*RHT959<L1
MMV.YM?'.@WGB1M!@NB]V"5#!?W;,.2H;N1S^5='7F_PY^'O]BK'K&K1_\3%E
M_<PGI;@CO_M$?E7I%.O&G&5J;N"N%%%%8C"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"LCQ)X
MBLO#&D2:A>DD#Y8XE/S2OV4?YXK7Z#)KYR\?>*'\3>(Y'C<FPM28K9>Q'=_J
M3^F*Z<+0]M.SV0F[&7XA\1:AXFU-KW4)<]1%$I^2)?11_7J:RJDMX)KJYBM[
M>)I9I6"1QJ,EF/0"O>?!/PZLO#L,=Y?HEUJI&2Q&5A]D]_\`:_E7KU:T,/&W
MW(A*YYKX6\`^([[4+&^^P&WM8YXY2]RVPE0P/"]>WI7T'117C5\1*L[LM*QF
M:])LTJ0?WV"_K_\`6IGAV,)II8`#?(3T_#^E7[JTBO(?*F!*YR,'!!K!U#4$
M@A&G6&0B_*S@Y)]A7EUG[*K[:6UK+U)>CN<[\2_$E_%IIT[2"R^;\LTT?WB.
MFQ<=SZ_@*3X=_#M=&2/5]7B#:B1F&$\BW'J?]O\`E76Z5HD</EW-U&K3J<QJ
M1GR__KUI7FHV6GQ&2]O(+=!_%+(%'ZUWT,35=#D:LV-)[LLT5R-[\3/"=D#_
M`,3,7##^&WC9_P!<8_6MW0];LO$.E1ZCI[LT$A(^==K*0<$$>M.5*<5S25D5
M<T:***@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@#E_B%J[:-X*OYHVVS3*+>,CL7XS^`R?PK
MYQ`P,#M7L_QJN&71-+MP?EDN6<C_`'5/_P`57C%>W@(VI7[F<MSU?X.^'$D:
MX\0W"`E&,%KGL<?.WZX_.O7ZYSP%:+9>!=(B48+6XE;W+?,?YUT=>7B:CG5;
M+6Q!=7<-G%YDS[1V'<_2LEO$L>[Y;9ROJ6`-96JW+76H2DGY4)1!Z`52KP*^
M.J<[4-$9N;OH=:E[#JUI+#;RF*9EQAN"/_K5%I>BBS;SIRKS#[H'1?\`Z]<U
M%*\$JRQG#H<@UW,,@F@CE'1U#?G6^&G'$2YIKWHE1?-N8>HV6JW%[)Y;MY!^
M[B3:`/I6%KG@"?7[-();V.##;BP0N?Z5WE5#JNG*Q5K^U#`X(,R\'\ZZZ>'4
M*OM8MW0^5'!67P9T.'!O+V]NCZ!A&OZ#/ZUW6D:18Z%IT=AIT`AMX\D+DDDG
MDDD\DU-#?V=Q)Y<%W!*^,[4D#'\A5BNNI6J3TFQI(9))'#$TLKJD:#<S,<`#
MU)KE6\>VUU*\>B:7J.KA#@RVT6(L_P"^V`:K>)8V\2>+K'PPSLNG1P_;;Y5.
M#*`<(A]L\FNR@@AM8$@@B2**,;41!@*/0"G:,$G+5L#ECXVGM!OU7PSJ]G"/
MO3+&LRK]=IS^E=%INIV.KV27FGW,=Q;OT=#W]#Z'V-6ZSK'0].TV_N[VSMA!
M-=X,VPD*Q'?;T!]\5+<&MK,9HT5RWQ%FEM_`U_)!+)%(#'AXV*L/WB]Q4"?#
MW3V12=5US)&?^0@].,(\O-)V`["BN0_X5YIV/^0KKO\`X,'KJK>%;:VB@5G9
M8D"!G;+$`8R3W-3)17PNX$M%<IX<FFD\:^+(WED>..6W"(S$A,QG.!VKJZ4X
M\KL`445R>CSS/\1_$D+2R-$D%J40L2JY4YP.@HC'F3?8#K****D`HK@M5TP:
M[\2I=/N+V_@MX]+68+:W+1_-YA&>/8U?_P"%>:=_T%=<_P#!@];.G!)<S_`1
MUU%<]I/@^ST?4$O8;_5)G52H2XNVD0Y]0:T=<U>#0M%NM3N03';INVCJQZ`#
MZG`J'%.5HZC-"D!!Z$'Z5Q-AX8OO$L":CXIO;D^<-\>FV\IBBA4]`V.6;'7)
MJX_P[T)/GL!>:?./NS6MTZL#Z\D@U3A!.SE^`CJZ*R=!M]9M+>6WUB[@O/+?
M$%PBE7D3_;'0-]*S[[P18W]_/=R:EJ\;S-N*17K*@^@["I48WLV,Z:BO,CX5
M@_X3P:+_`&KK/V0Z=]I_X_GW;_,V]?3':NFL?`]C87T%W'J6L2/"^\)+>LR'
MZCN*N5.$?M?@(Z>BBO/-:34?&?B"_LM*OY[2TTB(JLL+E1+=GD*2.H&,&IIP
MYWJ[(9Z'16'X3UW^W]!AN9%V7<9,-U$>"DJ\,/Z_C6Y42BXNS`**\XT?P_'X
MCUGQ'+>:EJD9M]3DBC6"\9%"\'&/QK9_X5YIW_05US_P8/6LJ<(NSE^`CKJ*
MX-(KSP?XNTFQBU.[O=,U0O$8;N3S&B=1D,K=<5WE1.'+:SNF,\N^-<+-I&DS
M`?*ERRG\5_\`K5XU7T1\2M*;5?`]Z(U+2VV+E`.^WK_X[NKYWKV,!*]*W8SE
MN?2W@:Z%WX'T>53G%LJ'ZK\I_45T%>4_!SQ`CVMSH$SXDC8SVX)^\I^\!]#S
M^->K5Y6(@X56F6MCB]2MVMM0F1AP6+*?4&JE=K?:?!?QA900P^ZXZBL9O#4V
M[Y;E"OJ5.:^?KX*HIMP5T9N#OH8BHTCJB#+,<`#N:[J"/R;>.+^XH7\A5+3]
M'@L6\PDR3?WB.GT%:-=N#PSI)N6[*C&PC,%4LQPH&23VKY0OI$N=1NK@*,2S
MO(./5B?ZU]!?$?Q`N@^$[A4?%W>`V\`[\CYF_`9_'%?.X&!@5]'ET&HN?<)'
M??!ZWW^-9)54`16;DD#U917O%>5?!;2FCLM2U9UQYSK!&?4+RWZD?E7JM<F.
MES5GY#CL<5J,JZ'\3K*_N#LM-4L_L?FGHLJMN4'ZBNUJEJVDV6MZ=)8:A`)8
M).H/!![$'L1ZUS<6C>+M&40Z7K-KJ%HO"1ZG&WF*/3>O7\:R]VHEK9H9V--$
MB,[('4NN-R@\C/3-<D\'CZ]'EO=Z+IRG@R01O*X^@;BM3P]X9M=`$\PFFN[^
MY(-S>3MEY".GT`]*EPC%:O49F_$O_D0M1^L7_HQ::G@.$QJ?^$A\0C('2^/^
M%:WBO19?$/ARZTR&9(9)BF'=20,,#T'TK(&F>.P`!X@TO`_Z<3_C6L)?NTE*
MVK_01MZ)H2:(DRIJ&H7GFD$F\G\PKCTXXK5KD/[-\>?]#!I?_@"?\:Z;3TO(
MM/A2_FCGNU7$LD:;58^H':LJBZN28SF?#/\`R//C#_KK;?\`HLUU]<9/X:\1
MV_B'5-2T?5[*WCOW1F2:V+D;5VCG/UJ3^S?'G_0P:7_X`G_&M)QC-W4ELN_;
MT$=?7(:+_P`E,\3_`/7"U_\`036YHD&LV]M(NM7MO=S%\HT$/E@+CH1GKG-8
M5[X;\0)XGU#5]&U6SMEO$B1TFMS(?D7'K]:F%ES1;W7ZH#L**Y#^S?'G_0P:
M7_X`G_&MK0[?6[>*8:U?VUVY8&(P0^6%&.0>>:F4$E?F3&<IJFD+K7Q1EMWO
M;VT":4C[[27RV/[PC!/IS6F?`4)&/^$B\0_^!Y_PHU?P[KDOBEM;T;4[2U=K
M1;9EG@,F0&+>OTIO]F^//^A@TO\`\`3_`(UOSMI<LDM/ZZ".LAC\F".(,S[%
M"[G.2<#J3ZUROQ)MI;CP5=/$A?[/)'.Z#^)%8%OTY_"I]/L?&$6H0OJ&M:?/
M:*W[V..T*LPQV.>.:Z5E5U*LH96&"",@BL4_9S4D[C(;*\@U"Q@N[619()D#
MHRG@@U/7'CPCJ6C32/X7U@6=O(Q8V-U'YL*D]=O.5^@ISZ?XYNQY<VM:59QG
MAGM;9F?'MN.`:'3BWI+01UH(.<$''!]J6LCP_P"'K7P_:RQPRS3SSOYEQ<3O
MN>5_4UKUG))/09R!_P"2N+_V!O\`VK77UB'1)?\`A-1KOG)Y0L?LOE;3NSOW
M9SZ5MU=1IVMV`Y[QGX@/A[P]-/"-U[,?)M8P,EI#TX[XZ_A7,^&/%.C^'=!@
ML!8ZR\PR\\OV!\R2-RS?G^@%=1<>'Y;[QA;ZQ>7"/:V416TM@I^61OO.QZ$X
MX%;]6IPC#EM?JQ'E^G^)K*Q\?FZM8+VWTW5]L=R+FV:)4N.BL">/FZ'\Z]0K
M,\0Z+!X@T.ZTV<[1*OR/CE''*L/H:GTJ&\MM*MH-0G2>ZCC"R2H"`Y'?!]:5
M249I-;[`<#H=GXAN=:\3-H^KVUE"-5E#I+:^:6;`YSGCC%:E]8>/K:QFGM]=
ML;F6-2RPK8A2^.P.>M;>@:'+H]UK$TDZ2"_O6ND"J1L!`&#ZGBMNJG6][1)K
MT"QPG@RS&OR6_BC4=4DO[Z)6A2$Q");1NC+M'\7N:[NN>B\.2V'BR35]-N$A
MMKQ<7UJRG$CCI(N.C>OK70U%:2E*ZV_+R!",JNC(ZAE88((X(KYJ\9^&Y/#'
MB.>RVG[*Y,MLY[QD]/J.G_ZZ^EJY_P`7^%;7Q9HYM)2([B,E[>?&3&W^![BM
M<)7]C/79@U<^<;"^N=,OX+ZSE,5Q`^^-QV/]0>A%?0O@[QQI_BNT50RP:DB_
MOK5CS_O+ZK_+O7S_`*KI5[HFHR6&H0&&XC/(/1AV*GN#ZU5BED@E26&1XY4.
M4=&(93Z@CI7JU\/"O&_7N0G8^LZ*\%T?XM>(=.C6*\6#48UX!E&V3_OH=?Q%
M=&OQMAV?/H,N[VN1C_T&O+E@:R>BN5S(]7K+U[Q#IOAO3VO-1G"+T2,<O(?1
M1W->3:G\9=8N49-.L;:SST=R96'\A^AK@-0U&]U6[:[U"ZEN9V_CD;.!Z#T'
ML*VI9?-N]31`Y=C0\4>);OQ3K+W]S\B`;((0<B)/3W/J:SK"PN=4U"WL+./?
M<7#A$7W/<^PZGZ5#%%)/,D,,;22R,%1$&68GH`*]V^'7@3_A&[<ZCJ*J=4G7
M&WJ($_NCW/<_A]>ZM5AAZ>GR1*5V=9H6D0Z#H=IIEOREO&%+?WFZEOQ.36C1
M17@MMN[-"C>ZSINFR+'>WT%N[#<JR.%)'K4,/B71+B58HM5LWD8X51,,DUB:
MT+H^-K;['96]W)_9[9CG?:H&\<YP>?\`&JNO6^L3:)=)/H6FPP[-TDL,H9T4
M<DJ-HY`Z<UO&E%I7Z^:%<[.YN[>RB$MS,D498(&8X&2<`?G4K,J*68A5`R23
MP*Y?Q/+'-X4LI869XWGMF1FZD%EP33_&)#II=M<,4T^XO%2Z.<`K@D*3Z$U"
MIWM\PN7O^$KT'S_)_M:UWYQ]_C/UZ5KJP90RD%2,@@\&J_\`9]E]E^S?9(/L
M^,>7Y8VX^E<[X7C633]:L89F&G1W,D-M(&SM4CD*?0$G%+EBTVN@&I-XIT*W
MF:*75+8.IPP#9P?<BM&VNK>\A$UK/'-&>CQL&'Z5S%AIGB'2=/CL[5-&N[9%
MPC.K(S#U.,@GWJYH%\&?4;#^S(;&]MF#RQPD%'+#(8$`=<54J<;7B%S1O]<T
MO2W"7M]!"YY",WS?EUJ6QU.QU.,R6-W%<*.OEMG'U':L'P5;VLVC_;G59=1F
MD<W<CC+A]Q^4^F!CBMH6&F1ZLETL4,=\8R`5.UF7OD#K^-*48Q;CU0%D7=N;
MPV@E3[0$\PQYYVYQGZ9JI=Z]I-A<&"[U&V@F`!*22`$9K/3_`)*'+_V#!_Z,
MK,FBOY?&NK?8+:PG(@@W_:\X'!QC`-.---Z]KA<Z*V\0Z/>W"6]MJ=K-,_W4
M20$GOTJS)?VD-Y%9R7,27,HS'$S`,P]A572K6X6,O?V=A%<!OD-J"1MQZD`Y
MZUB:UID&K>,X;6?<,Z<S)(APT;B0893ZBDHQ<K=`.IN+B&TMWGN)%BAC&YW<
MX"CWJ165T#J0589!'<5Q&KZI<KX:U;1]6P-0BMF:.0#"W*?WU]_45?\`$\LL
M7@N/RW:.-Q"D[IU6(D!C^5/V6R[L+FE-XIT*"<PR:K;"0'!&_./J1Q6I#-%<
M1++#(DD;#*NC9!_&JUGI^GV]E'#:6T"V^T;0J@@C^M)IUGI]DL\>GI%&IE+2
M)&V0'[\=OI4/EMI<95;Q3H*L5;5[,,#@@RCBK=CJVGZF9!8WD-QY>-_E.&VY
MZ9_*N-\-P:Q)HRM:6&D2PF67:]SNWGYVSG`]:[6S@\JW0O!!%,RCS1",+N[X
M]JNI",=$)%.Z\2:+97#07&I6Z2J<,F[)7ZXZ5=L[^TU"'S;.YBGC_O1N&Q7,
MZ?I&N:/;O!IS:5>6S.SJ\RLLC9.?F(R#]:MZ%>E-9N].NM*MK*^,:SN]L04E
M7.,YP#GZT2IQL^77^NP7.CHHHK$84444`%%%%`!1110`4444`%%%%`&/XA\,
MZ7XGLOLVHP;BO^KE7AXSZJ?Z=*\<\0?"K7=*=I-/4:G:CH8QB4#W7O\`A^5>
M]T5T4<34I:+8329\F7$$UI*8KF&2"0=4E0J1^!J/(]17UC<6EM=ILN;>*9?2
M1`P_6LYO"OAYGWG0].+>OV9/\*[5F2ZQ)Y3Y@7YV"("S'HJC)/X5U6A_#OQ'
MKC*RV9L[<]9KH%!CV7J?RKZ"M=-L++_CTLK:#_KE$J_R%6JB>8R:]Q6'RG*>
M$_`6E>%5$T8-U?D8:ZE'(]E'\(_7WKJZ**\^<Y3?-)W904445(&5J?AZQU6[
MCNK@W"S(GEJT,S1_+G..#5/_`(0S2FXE:]F3O')=R,K?49KH:*M5)I63"Q2O
M=+M+^RCM)HR(8V1E5#MP5.1T[<5/=6MO?6TEM=1)+#(,,CC(-345-V!SW_"'
MV&WROM6H_9_^??[6^S'ICKC\:V(K"T@L!8Q6\:6H0IY0'R[3U%6:*;G)[L#`
M7PC8PY6TN]1M(C_RR@NV"#Z#G%:.F:19Z1"\=I&09&W2.[%G<^I)Y-7J*;G)
MJS86,:[\,:?=7CW<;7-I<2?ZR2TF,9?Z@<$U+IWA^PTRX:YC626Z88-Q<2&2
M3'ID]!]*U**.>5K7"Q5&GVXU5M2"M]I:'R2=W&W.>GUJA?>&-/O[^2]E:Z2>
M10K&&X9`0.G0ULT4E.2U3`Q+7PO8VEU%<1SWQ>-MRA[MV4_4$X-:+:?;MJB:
MB5;[2D)A!W<;2<]/K5JBASD]V!GZOHEAKEJMO?P[U4[E8$JRGV(JW]GB-K]F
M9`\.S8589!&,8-2T4N9VL!S_`/PA^GH"EO<ZA;0G_EA#=LJ?EVK5T[3+/2K;
M[/90+%'G)QR6/J2>2?K5NBFYR:LV%CGE\%Z6F1')?1J23M2[=1DG)X!J]INA
M6NER2/!)=.9%VL)IVD&/8$\5IT4W4FU9L+&#_P`(CI\3LUG/?62L<E+6Y9%_
M+H*NZ9HEEI+2R6ZNTTO^LFF<N[_4FM&BAU)-6;"P4445`!1110`4444`%%%%
(`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
